C. difficile is the number one cause of infectious diahrrea in the developed world. Long thought to be a nuisance, the infections are turning deadly, and a spate of outbreaks has occurred at hospitals in the US, Canada, and Europe. Biotechs are racing to develop new therapeutics to combat the killer bug.
By Ellen Foster Licking
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
